Cancer pathogenesis and therapy最新文献_第3页

Handy “tools” for studying brain tumors 研究脑肿瘤的便捷 "工具

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/j.cpt.2024.06.009

Gangfeng Yu, Fanghui Lu, Liangxue Zhou

引用次数: 0

A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer EGFR突变阳性非小细胞肺癌患者EGFR-酪氨酸激酶抑制剂治疗的贝叶斯网络meta分析

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/j.cpt.2024.06.004

Jianqiong Yin , Jing Huang , Min Ren , Rui Tang , Linshen Xie , Jianxin Xue

{"title":"A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer","authors":"Jianqiong Yin , Jing Huang , Min Ren , Rui Tang , Linshen Xie , Jianxin Xue","doi":"10.1016/j.cpt.2024.06.004","DOIUrl":"10.1016/j.cpt.2024.06.004","url":null,"abstract":"<div><h3>Background</h3><div>To date, no direct comparisons have been performed to compare the effectiveness of all epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) against <em>EGFR</em> mutation-positive non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of EGFR-TKIs in patients with <em>EGFR</em> mutation-positive NSCLC.</div></div><div><h3>Methods</h3><div>We conducted a network meta-analysis of randomized controlled trials comparing osimertinib, lazertinib, aumolertinib, befotertinib, furmonertinib, dacomitinib, afatinib, erlotinib, gefitinib, icotinib, and chemotherapy. Pooled estimations of progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicity (grade ≥ 3 adverse events) were performed within the Bayesian framework.</div></div><div><h3>Results</h3><div>Twenty-three trials involving 11 treatments were included. All EGFR-TKIs improved PFS relative to chemotherapy, except for icotinib (hazard ratio [HR] = 0.61, 95% confidence interval [CI]: 0.26–1.44). All EGFR-TKIs demonstrated significant ORR benefits over chemotherapy. Osimertinib seemed to prolong PFS compared with icotinib (HR = 0.29, 95% CI: 0.1–0.86), gefitinib (HR = 0.39, 95% CI: 0.21–0.74), and erlotinib (HR = 0.53, 95% CI: 0.29–1.0). In addition, osimertinib showed favorable superiority in improving OS compared with chemotherapy (HR = 0.6, 95% CI: 0.43–0.82), gefitinib (HR = 0.61, 95% CI: 0.45–0.83), erlotinib (HR = 0.65, 95% CI: 0.48–0.89), and afatinib (HR = 0.65, 95% CI: 0.44–0.94). Among these regimens, afatinib showed the highest ORR (cumulative probability: 96.96%). Icotinib was associated with minimal toxicity among the EGFR-TKIs, followed by furmonertinib and osimertinib. Moreover, the toxicity spectra differed among the EGFR-TKIs. Subgroup analyses of patients with two common types of <em>EGFR</em> mutations indicated that furmonertinib possessed the greatest PFS benefit in patients with exon 19 deletion, and lazertinib showed the greatest PFS benefit in patients with Leu858Arg mutation. We also identified differences between EGFR-TKIs in prolonging PFS in patients with brain metastasis.</div></div><div><h3>Conclusions</h3><div>Osimertinib is the first choice of treatment with considerable efficacy and safety for <em>EGFR</em> mutation-positive NSCLC. The treatments associated with the best PFS in patients with exon 19 deletions and Leu858Arg mutations were furmonertinib and lazertinib, respectively.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Pages 135-146"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of skin cancer types and prevalence rates across continents 各大洲皮肤癌类型和发病率概览

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/j.cpt.2024.08.002

Amdad Hossain Roky , Mohammed Murshedul Islam , Abu Mohammed Fuad Ahasan , Md Saqline Mostaq , Md Zihad Mahmud , Mohammad Nurul Amin , Md Ashiq Mahmud

{"title":"Overview of skin cancer types and prevalence rates across continents","authors":"Amdad Hossain Roky , Mohammed Murshedul Islam , Abu Mohammed Fuad Ahasan , Md Saqline Mostaq , Md Zihad Mahmud , Mohammad Nurul Amin , Md Ashiq Mahmud","doi":"10.1016/j.cpt.2024.08.002","DOIUrl":"10.1016/j.cpt.2024.08.002","url":null,"abstract":"<div><div>Skin cancer is one of the most prevalent cancers in the world, and its incidence and mortality rates are increasing continuously, mostly in regions with white-skinned inhabitants. The types of skin cancer vary in their origin and clinical appearances and also differ in their extensiveness. The continents of the world have different scenarios of skin cancer prevalence. This review aims to explore the different types of skin cancer, their clinical features, and their worldwide prevalence based on the literature. Literature from different electronic databases, including Google Scholar, ResearchGate, PubMed, Scopus, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Elsevier, and Springer, were collected through a literature search using specific keywords such as “skin cancer”, “skin cancer types”, “melanoma”, “non-melanoma”, “skin cancer continental prevalence” or similar keywords. The search included English publications from 2000 to 2024. Melanoma skin cancer (MSC) ranks 17th in global prevalence, with the highest incidence and deaths occurring in Europe, However, Australia and New Zealand record the highest incidence and mortality rates. Asia has a lower incidence rate of melanoma, but a higher mortality rate. Superficial spreading melanoma (SSM) is the most common type of MSC. Non-melanoma skin cancers (NMSCs) have the highest incidence in North America, with the highest number of deaths occurring in Asia, Australia and New Zealand have the highest incidence rates for basal cell carcinoma (BCC). BCC is the most commonly diagnosed skin cancer worldwide and the most prevalent form of NMSCs; however, squamous cell carcinoma is the most aggressive form of NMSCs, causing more deaths. NMSCs are the most prevalent cancers worldwide, causing most skin cancer-related deaths. The prevalence of skin cancer rising globally, with several continents experiencing higher incidence and mortality rates. The types and subtypes of skin cancer are becoming more common among clinically diagnosed cancers. This review comprehensively describes skin cancer types and their prevalence worldwide. However, the actual prevalence of skin cancer in these countries should be investigated. Further research on the prevalence of skin cancer across different continents is required to develop more effective cancer management strategies and control the spread of the disease.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 2","pages":"Pages 89-100"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating multi-omics methods for personalized treatment of refractory chronic myelomonocytic leukemia with NRAS and TET2 mutations 整合多组学方法个体化治疗NRAS和TET2突变难治性慢性髓细胞白血病

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/j.cpt.2024.12.001

Chuandong Hou , Bo Yang , Yue Wang , Lili Cai , Ran Qin , Bo Guo , Jie Geng , XueChun Lu

引用次数: 0

Gastrointestinal stromal tumors with an uncommon primary mutation responded well to imatinib 具有罕见原发性突变的胃肠道间质瘤对伊马替尼反应良好

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/j.cpt.2024.08.005

Gilani Shahid, Mujeeb Qudsia, Ikram Naima, Khir Ibrahim

引用次数: 0

Cover 封面

Cancer pathogenesis and therapy Pub Date : 2025-03-01 DOI: 10.1016/S2949-7132(25)00018-7

引用次数: 0

Loss of phosphatase and tensin homolog (PTEN) increases Lysyl oxidase-like 2 (LOXL2) expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids PTEN 缺失会增加 LOXL2 的表达，从而促进输卵管上皮细胞作为三维球体的生长

Cancer pathogenesis and therapy Pub Date : 2025-01-01 DOI: 10.1016/j.cpt.2024.03.003

Angela Russo , Junlone Moy , Manead Khin , Timothy R. Dorsey , Alfredo Lopez Carrero , Joanna E. Burdette

{"title":"Loss of phosphatase and tensin homolog (PTEN) increases Lysyl oxidase-like 2 (LOXL2) expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids","authors":"Angela Russo , Junlone Moy , Manead Khin , Timothy R. Dorsey , Alfredo Lopez Carrero , Joanna E. Burdette","doi":"10.1016/j.cpt.2024.03.003","DOIUrl":"10.1016/j.cpt.2024.03.003","url":null,"abstract":"<div><h3>Background</h3><div>High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of all ovarian cancer-related deaths. Multiple studies have suggested that the fallopian tube epithelium (FTE) serves as the cell of origin of HGSOC. Phosphatase and tensin homolog (<em>PTEN</em>) is a tumor suppressor and its loss is sufficient to induce numerous tumorigenic changes in FTE, including increased migration, formation of multicellular tumor spheroids (MTSs), and ovarian colonization. In murine oviductal epithelial (MOE) cells (the equivalent of human FTE) loss of <em>PTEN</em> results in the upregulation of transcripts associated with the extracellular matrix, with a specific focus on the elevation of lysyl oxidase-like 2 (<em>LOXL2</em>). Although LOXL2 is known to drive transformation and invasion in solid tumors and is associated with a poor prognosis in ovarian cancer, its specific role in the tumorigenesis of ovarian cancer originating from FTE remains unclear. Therefore, we aim to investigate whether LOXL2 mediates tumorigenesis from the fallopian tube epithelium.</div></div><div><h3>Methods</h3><div>In this study, we utilized clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (CAS9) technology to delete <em>LOXL2</em> in <em>PTEN</em>-deficient MOE cells to understand its role in mediating the oncogenic effects of PTEN loss. In addition, CRISPR-CAS9 was used to delete LOXL2 in OVCAR8 ovarian cancer cells. We monitored the changes in tumorigenic properties, such as migration, invasion, and growth of three-dimensional (3D) spheroids, to assess whether the loss of LOXL2 resulted in any changes.</div></div><div><h3>Results</h3><div>We found that a reduction in LOXL2 expression did not significantly change the migration or invasive capabilities of PTEN-depleted MOE or human ovarian cancer cells. However, we found that a reduction in LOXL2 expression resulted in a significant reduction in 3D MTS formation and survival in both lines.</div></div><div><h3>Conclusions</h3><div>These results reveal for the first time that <em>PTEN</em> loss in FTE cells increases <em>LOXL2</em> expression through downregulation of <em>Pax2</em>, and LOXL2 deletion blocks 3D spheroid formation.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 68-75"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140399558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Three-dimensional (3D) augmented reality during Retzius-sparing robot-assisted radical prostatectomy (RS-RARP): First experience 三维（3D）增强现实在Retzius-sparing机器人辅助根治性前列腺切除术（RS-RARP）：第一次体验。

Cancer pathogenesis and therapy Pub Date : 2025-01-01 DOI: 10.1016/j.cpt.2024.06.003

Silvia Secco , Alberto Olivero , Stefano Tappero , Paolo Dell’Oglio , Luca Carbonaro , Alessandro Marando , Angelo Vanzulli , Emanuela Bonoldi , Aldo Massimo Bocciardi , Antonio Galfano

引用次数: 0

Biochemical mechanisms and molecular interactions of vitamins in cancer therapy 维生素在癌症治疗中的生化机制和分子相互作用

Cancer pathogenesis and therapy Pub Date : 2025-01-01 DOI: 10.1016/j.cpt.2024.05.001

Abdullahi T. Aborode , Isreal A. Onifade , Mercy M. Olorunshola , Gladys O. Adenikinju , Ibude J. Aruorivwooghene , Adeboboye C. Femi , Osasere Jude-Kelly Osayawe , Abraham Osinuga , Ebenezer A. Omojowolo , Adekunle F. Adeoye , Segun Olapade , Ibrahim O. Adelakun , Ogundepo D. Moyinoluwa , Oluwatosin M. Adeyemo , Godfred Y. Scott , Ruth A. Ogbonna , Emmanuel A. Fajemisin , Omama Ehtasham , Soyemi Toluwalashe , Adetolase A. Bakre , Terungwa H. Iorkula

{"title":"Biochemical mechanisms and molecular interactions of vitamins in cancer therapy","authors":"Abdullahi T. Aborode , Isreal A. Onifade , Mercy M. Olorunshola , Gladys O. Adenikinju , Ibude J. Aruorivwooghene , Adeboboye C. Femi , Osasere Jude-Kelly Osayawe , Abraham Osinuga , Ebenezer A. Omojowolo , Adekunle F. Adeoye , Segun Olapade , Ibrahim O. Adelakun , Ogundepo D. Moyinoluwa , Oluwatosin M. Adeyemo , Godfred Y. Scott , Ruth A. Ogbonna , Emmanuel A. Fajemisin , Omama Ehtasham , Soyemi Toluwalashe , Adetolase A. Bakre , Terungwa H. Iorkula","doi":"10.1016/j.cpt.2024.05.001","DOIUrl":"10.1016/j.cpt.2024.05.001","url":null,"abstract":"<div><div>Recently, the potential role of vitamins in cancer therapy has attracted considerable research attention. However, the reported findings are inconsistent, with limited information on the biochemical and molecular interactions of different vitamins in various cancer cells. Importantly, the presence of vitamin receptors in tumor cells suggests that vitamins play a significant role in the molecular and biochemical interactions in cancers. Additionally, studies on the efficacy of vitamin supplementation and dosage levels on tumor progression and mortality risk have yielded inconsistent results. Notably, molecular and biochemical investigations have reported the function of vitamins in the proliferation, growth, and invasiveness of tumor cells, as well as in cell cycle arrest and inflammatory signaling. Additionally, different vitamins may regulate the cancer microenvironment by activating various molecular pathways. Vitamins significantly affect immunological function, antioxidant defense, inflammation, and epigenetic control, and can improve treatment outcomes by affecting cell behavior and combating stress and DNA damage. However, further research is necessary to confirm the efficacy of vitamins, establish ideal dosages, and develop effective cancer prevention and treatment plans. Individualized supplementation plans guided by medical knowledge are crucial to achieving optimal results in clinical and preclinical settings. In this review, we critically evaluated the effects of different vitamins on the risk and development of cancer. Additionally, we examined the potential of vitamin supplements to enhance the efficacy of drug therapy and counteract resistance mechanisms that often arise during cancer treatment.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 3-15"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141030686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative analysis of cuproptosis-related lncRNAs: Unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer 杯突相关lncRNA的整合分析：揭示前列腺癌的预后意义、免疫微环境和铜诱导机制

Cancer pathogenesis and therapy Pub Date : 2025-01-01 DOI: 10.1016/j.cpt.2024.03.004

Haitao Zhong , Yiming Lai , Wenhao Ouyang , Yunfang Yu , Yongxin Wu , Xinxin He , Lexiang Zeng , Xueen Qiu , Peixian Chen , Lingfeng Li , Jie Zhou , Tianlong Luo , Hai Huang

{"title":"Integrative analysis of cuproptosis-related lncRNAs: Unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer","authors":"Haitao Zhong , Yiming Lai , Wenhao Ouyang , Yunfang Yu , Yongxin Wu , Xinxin He , Lexiang Zeng , Xueen Qiu , Peixian Chen , Lingfeng Li , Jie Zhou , Tianlong Luo , Hai Huang","doi":"10.1016/j.cpt.2024.03.004","DOIUrl":"10.1016/j.cpt.2024.03.004","url":null,"abstract":"<div><h3>Background</h3><div>Long non-coding ribonucleic acids (lncRNAs) regulate messenger RNA (mRNA) expression and influence cancer development and progression. Cuproptosis, a newly discovered form of cell death, plays an important role in cancer. Nonetheless, additional research investigating the association between cuproptosis-related lncRNAs and prostate cancer (PCa) prognosis is required.</div></div><div><h3>Methods</h3><div>Sequencing data and copy number variant data were obtained from 492 patients with PCa from The Cancer Genome Atlas (TCGA) Program. Prognostic models of PCa based on cuproptosis-related lncRNAs were constructed using a multi-level attention graph neural network (MLA-GNN) deep learning algorithm. Immune escape scoring was performed using Tumor Immune Dysfunction and Exclusion. Cellular experiments were conducted to explore the correlation between key lncRNAs and cuproptosis.</div></div><div><h3>Results</h3><div>Data from 492 patients with PCa were randomized into two groups at a 1:1 ratio. Prognostic modeling was successfully established using MLA-GNN. Survival analysis suggested that patients could be divided into high- and low-risk groups according to model scores and that there was a significant difference in disease-free survival (DFS) (<em>P</em> < 0.01). The area under the receiver operating characteristic (ROC) curve (AUC) indicated a strong predictive performance for the model, with AUCs of 0.913, 0.847, and 0.863 for the training group and 0.815, 0.907, and 0.866 for the test group at 12, 36, and 60 months, respectively. The immune escape score and immune microenvironment analysis suggested that the high-risk group corresponded to a stronger immune escape and a poorer immune microenvironment (<em>P</em> < 0.05). Cellular experiments revealed that the expression of all six key lncRNAs was upregulated in the presence of copper ion carriers (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>This study identified cuproptosis-related lncRNAs that were strongly associated with PCa prognosis. Key lncRNAs could affect copper metabolism and may serve as new therapeutic targets.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 48-59"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140401211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0